Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction

References

• Gordon DA, Hastings DE. Rheumatoid arthritis clinical features. In: Klippel JH, Dieppe PA, eds. Rheumatology. St. Louis: CV Mosby, 1994:1–14.
   Google Scholar
• Emery P, Luqmani R. The validity of surrogate markers in rheumatic disease. Br J Rheumatol 1993;32 Suppl 3:3–8.
   PubMedGoogle Scholar
• Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994;24:91–104.
   PubMed Web of Science ®Google Scholar
• van Leeuwen MA, van der Heijde DMFM, van Rijswijk MH, Houtman PM, van Riel PLCM, van de Putte LBA, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts and acute phase reactants. J Rheumatol 1994;21:425–9.
   Google Scholar
• Scott DL, Coulton BL, Popert AJ. Long term progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 1986;45:373–8.
   PubMed Web of Science ®Google Scholar
• Kirwan JR. The relationship between synovitis and erosions in rheumatoid arthritis. Br J Rheumatol 1997;36:225–8.
   PubMedGoogle Scholar
• Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32: 949–55.
   Google Scholar
• Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268: 25803–10.
   Google Scholar
• Shackelton LM, Mann DM, Millis AJT. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995;270: 13076–83.
   Google Scholar
• Hu B, Trinh K, Figueira WF, Price PA. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem 1996;271:19415–20.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Olee T, Price PA, Hashimoto S, Ochs RL, Lotz M. Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 2001;44: 826–37.
   PubMed Web of Science ®Google Scholar
• Volck B, Johansen JS, Stoltenberg M, Garbarsch C, Price PA, Ostergaard M, et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001;9:203–14.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick RB, Emery JG, Connor JR, Dodds R, Lysko PG, Rosenberg M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 1997;237:46–54.
   PubMed Web of Science ®Google Scholar
• Renkema GH, Boot GR, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998;251: 504–9.
   Google Scholar
• Rehli M, Krause SW, Andreesen R. Molecular characteriza-tion of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997;43: 221–5.
   Google Scholar
• Baeten D, Boots AMH, Steenbakkers PGA, Elewaut D, Bos E, Verheijden GFM, et al. Human cartilage gp-39+, CD16 + monocytes in peripheral blood and synovium. Correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000;43:1233–43.
   PubMed Web of Science ®Google Scholar
• Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998;110: 351–60.
   Google Scholar
• Recklies AD, Baillargeon L, Ling H. HC-gp39 is a growth factor for connective tissue cells. Arthritis Rheum 2000;43 Suppl: Abstract 1686.
   Google Scholar
• Verheijden GFM, Rijnders AWM, Bos E, Coenen-De Roo CH, van Staveren CJ, Miltenburg AMM, et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheum-atoid arthritis. Arthritis Rheum 1997;40: 1115–25.
   Google Scholar
• Cope AP, Patel SD, Hall F, Congia M, Hubers HAJM, Verheijden GF, et al. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and non-associated HLA-DR4 alleles. Arthritis Rheum 1999;42:1497–507.
   PubMed Web of Science ®Google Scholar
• Joosten LAB, Coenen-De Roo CH, Helsen MMA, Lubberts E, Boots AMH, van den Berg WB, et al. Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice. Amelioration of clinical, histologic, and radiolo-gic signs of type II collagen-induced arthritis. Arthritis Rheum 2000;43:645–55.
   PubMed Web of Science ®Google Scholar
• Vos K, Miltenburg AMM, van Meijgaarden KE, van den Heuvel M, Elferink DG, van Galen PJM, et al. Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions. Rheumatology 2000;39:1326–31.
   Google Scholar
• Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J, et al. Chondrex: new marker of joint disease. Clin Chem 1998;44:509–16.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Stoltenberg M, Hansen M, Florescu A, Horsley-Petersen K, Lorenzen I, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 1999;38: 618–26.
   Google Scholar
• Vos K, Steenbakkers P, Miltenburg AMM, Bos E, van den Heuvel MW, van Hogezand RA, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000;59:544–8.
   Google Scholar
• Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996;35: 553–9.
   Google Scholar
• Kirwan JR, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorti-coids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142–6.
   Google Scholar
• Hickling P, Jacoby RK, Kirwan JR, and the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998;37:930–6.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arth-ritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Sharif M, Salisbury C, Taylor DJ, Kirwan JR. Changes in biochemical markers of joint tissue metabolism in a random-ized controlled trial of glucocorticoid in early rheumatoid arthritis. Arthritis Rheum 1998;41:1203–9.
   PubMed Web of Science ®Google Scholar
• Larsen A, Dale K, Eek M. Radiographic evaluation of rheum-atoid arthritis and related conditions by standard reference films. Acta Radiol 1977;18:481–91.
   Google Scholar
• Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206–9.
   PubMedGoogle Scholar
• Thompson PW, Silman AJ, Kirwan JR, Currey HLF. Articular indices of joint inflammation in rheumatoid arthritis: correla-tion with the acute phase response. Arthritis Rheum 1987;30:618–23.
   PubMed Web of Science ®Google Scholar
• Sharif M, Kirwan JR, Elson CJ, Dieppe PA, Shepstone L. Elevated serum C-reactive protein may reflect events which precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis 2000;59:71–4.
   Google Scholar
• Goldberg RL. Enzyme-linked immunosorbent assay for hyalu-ronate using cartilage proteoglycan and an antibody to keratan sulphate. Anal Biochem 1988;174:448–58.
   PubMed Web of Science ®Google Scholar
• Thonar EJ-MA, Lenz ME, Klintworth GK, et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum 1985;28:1367–76.
   Google Scholar
• Taylor DJ, Cheung NT, Davies PT. Increased serum proMMP-3 in inflammatory arthritis: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 1994;53: 768–72.
   Google Scholar
• Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230–5.
   PubMed Web of Science ®Google Scholar
• Gamer° P, Jouvenne P, Delmas P, Milossec P. Serum YKL-40 and joint destruction in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 1999; 14th European League against Rheumatism (EULAR): abstract no 222.
   Google Scholar
• Harvey S, Whaley J, Eberhardt K. The relationship between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis. Scand J Rheumatol 2000;29: 391–3.
   Google Scholar
• Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosions differ. Br J Rheumatol 1996;35: 1263–8.
   Google Scholar
• Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74–80.
   PubMedGoogle Scholar